0000899243-17-024268.txt : 20171016
0000899243-17-024268.hdr.sgml : 20171016
20171016171713
ACCESSION NUMBER: 0000899243-17-024268
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171013
FILED AS OF DATE: 20171016
DATE AS OF CHANGE: 20171016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blobel Friedhelm
CENTRAL INDEX KEY: 0001363213
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 171139382
MAIL ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-13
1
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001363213
Blobel Friedhelm
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
1
1
0
0
President, CEO, Director
Common Stock
2017-10-13
4
M
0
95000
A
237299
D
Common Stock
2017-10-13
4
A
0
150000
0.00
A
387299
D
Common Stock
2017-10-13
4
D
0
387299
11.18
D
0
D
Non-Qualified Stock Option (right to buy)
5.13
2017-10-13
4
D
0
142610
6.05
D
2021-05-12
Common Stock
142610
0
D
Non-Qualified Stock Option (right to buy)
6.22
2017-10-13
4
D
0
200000
4.96
D
2022-03-15
Common Stock
200000
0
D
Non-Qualified Stock Option (right to buy)
4.53
2017-10-13
4
D
0
200000
6.65
D
2023-04-04
Common Stock
200000
0
D
Non-Qualified Stock Option (right to buy)
4.52
2017-10-13
4
D
0
200000
6.66
D
2024-03-14
Common Stock
200000
0
D
Incentive Stock Option (right to buy)
8.83
2017-10-13
4
D
0
42725
2.35
D
2025-03-16
Common Stock
42725
0
D
Restricted Stock Unit
2017-10-13
4
M
0
10000
D
Common Stock
10000
0
D
Non-Qualified Stock Option (right to buy)
8.83
2017-10-13
4
D
0
97275
2.35
D
2025-03-16
Common Stock
97275
0
D
Restricted Stock Unit
2017-10-13
4
M
0
50000
D
Common Stock
50000
0
D
Incentive Stock Option (right to buy)
9.12
2017-10-13
4
D
0
11243
2.06
D
2026-03-15
Common Stock
11243
0
D
Non-Qualified Stock Option (right to buy)
9.12
2017-10-13
4
D
0
128757
2.06
D
2026-03-15
Common Stock
128757
0
D
Restricted Stock Unit
2017-10-13
4
M
0
15000
D
Common Stock
15000
0
D
Incentive Stock Option (right to buy)
9.65
2017-10-13
4
D
0
10843
1.53
D
2027-03-08
Common Stock
10843
0
D
Non-Qualified Stock Option (right to buy)
9.65
2017-10-13
4
D
0
129157
1.53
D
2027-03-08
Common Stock
129157
0
D
Restricted Stock Unit
2017-10-13
4
M
0
20000
D
Common Stock
20000
0
D
Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
Includes 216 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on October 6, 2017 and 746 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on August 31, 2017.
Shares of SCLN common stock received in settlement of performance rights not constituting derivative securities.
Granted under Issuer's 2005 Equity Incentive Plan.
Under its terms the option became exercisable in installments with 25% vesting on April 5, 2012 and 2.0833% vesting each month thereafter until it became vested in full on April 5, 2015.
The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
Under its terms the option became exercisable in installments with 25% vesting on March 15, 2013 and 2.0833% vesting each month thereafter until it became vested in full on March 15, 2016.
Under its terms the option became exercisable in installments with 25% vesting on April 4, 2014 and 2.0833% vesting each month thereafter until it became vested in full on April 4, 2017.
Under its terms the option became exercisable in installments with 25% vesting on March 14, 2015 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.
Granted under Issuer's 2015 Equity Incentive Plan.
Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
Under its terms the option became exercisable in installments with 25% to vest on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
/s/ Friedhelm Blobel, Ph.D.
2017-10-16